-
J Clin Oncol: Domestic multicenter phase III study shows that preoperative short-course radiotherapy + chemotherapy (TNT) is a feasible treatment option for locally advanced rectal cancer
Time of Update: 2022-04-22
Patients were randomly assigned (1:1) to short-term radiotherapy (25 Gy, divided into 5 sessions over 1 week) followed by 4 cycles of chemotherapy (total neoadjuvant therapy [TNT]) or chemoradiation (50 Gy, divided into 25 sessions over 5 sessions) Weeks, concurrent use of capecitabine [chemochemotherapy; CRT]) .
-
Eur J Cancer: Real clinical efficacy of MEK inhibitors in NRAS-mutant metastatic melanoma
Time of Update: 2022-04-22
MEK inhibitors (MEKi) have shown clinical efficacy in NRAS-mutated metastatic melanoma in randomized controlled trials, but their clinical use is currently limited to advanced, pretreated patients, in contrast to previous trials.
-
J Immunother Cancer: The efficacy of nivolumab (nivolumab) combined with cabozantinib (cabozantinib) in patients with advanced endometrial cancer
Time of Update: 2022-04-22
immune blood vesselsThe researchers randomized patients with recurrent endometrial cancer in a 2:1 ratio to nivolumab in combination with cabozantinib (arm A) and nivolumab alone (arm B), with the primary endpoint being progression-free survival (PFS) .
-
Clin Cancer Res: Phase III clinical study CATNON showed that in IDH wild-type glioblastoma, the addition of temozolomide to radiotherapy did not improve patient outcomes
Time of Update: 2022-04-22
Recently, the journal CLINICAL CANCER RESEARCH published the results of a post-hoc analysis of a phase III clinical study CATNON (NCT00626990), which mainly evaluated whether the addition of temozolomide to radiotherapy in IDH wild-type glioblastoma improved patients.
-
Br J Dermatol: Do we need to reconsider the diagnosis of melanoma in situ and severely dysplastic nevi?
Time of Update: 2022-04-22
The first is the evidence on the natural history of these lesions, which we found to be rare, as melanoma in situ and severe dysplastic nevi are usually excised .
This provides evidence for a lowering of the diagnostic threshold and expansion of disease definitions for melanoma in situ and severe dysplastic nevi .
-
JAMA Dermatol: Does Spironolactone Really Cause Increased Cancer Risk?
Time of Update: 2022-04-22
Given this official warning and uncertainty about the potential link between spironolactone use and cancer, the aim of this study was to conduct a systematic review and meta-analysis to synthesize the evidence on cancer risk from spironolactone use .
-
J Clin Oncol: Olaparib ± cediranib vs chemotherapy in recurrent platinum-sensitive ovarian cancer
Time of Update: 2022-04-22
The patients were randomized (1:1:1) into three groups to receive platinum-based chemotherapy, olaparib, and olaparib/cediranib, respectively .
In short, the olaparib/cediranib combination did not prolong progression-free survival in ovarian cancer patients compared with chemotherapy .
-
JNCC: Hejie academician team released the latest cancer incidence and mortality data in China
Time of Update: 2022-04-22
The mortality rates of colorectal cancer, breast cancer, thyroid cancer, prostate cancer and other tumors with high incidence in developed countries show a continuous upward trend .
-
Clin Cancer Res: Efficacy of temozolomide combined with radiotherapy vs radiotherapy alone in IDH wild-type glioblastoma
Time of Update: 2022-04-22
Does adjuvant radiotherapy combined with temozolomide improve outcomes in patients with anaplastic astrocytoma without IDH1/2 mutations with molecular features of glioblastomaThe CATNON trial was a randomized phase 3 study to investigate the effect of adjunctive or concurrent use of temozolomide during radiotherapy in patients with anaplastic astrocytoma .
-
Oncologist: Patients with locally advanced rectal cancer (LARC) treated with complete neoadjuvant therapy (TNT) did not improve prognosis
Time of Update: 2022-04-22
Therefore, a team from the United States conducted a retrospective study to evaluate the efficacy and prognosis of TNT + surgery versus neoadjuvant chemoradiotherapy + surgery + adjuvant chemotherapy in patients with locally advanced rectal cancer (LARC) .
-
J Clin Oncol: Efficacy of temozolomide in combination with low-dose ipilimumab and nivolumab in MSS and MGMT-deficient metastatic colorectal cancer (mCRC)
Time of Update: 2022-04-22
The primary endpoint was the 8-month progression-free survival (PFS) rate (calculated from the second part of treatment) .
The primary endpoint was the 8-month progression-free survival (PFS) rate (calculated from the second part of treatment) .
-
Selective estrogen receptor degrader (SERD) amcenestrant in breast cancer fails to meet primary endpoint
Time of Update: 2022-04-22
The AMERA-3 trial evaluated the efficacy of oral amcenestrant as monotherapy versus physician-chosen endocrine therapy in patients with locally advanced or metastatic estrogen receptor-positive (ER+)/HER2-negative breast cancer that progressed during or after hormone therapy .
com/story/5524831 https://firstwordpharma.
com/story/5524831 https://firstwordpharma.
-
J Clin Oncol: Clinical efficacy of nivolumab-tailored therapy in patients with advanced urothelial carcinoma
Time of Update: 2022-04-22
The study's tailored nivolumab therapy demonstrated significant clinical activity, supporting the use of dual checkpoint inhibitors as first-line therapy in patients with metastatic urothelial carcinoma .
The study's tailored nivolumab therapy demonstrated significant clinical activity, supporting dual-checkpoint inhibitor therapy in first-line treatment of patients with metastatic urothelial carcinoma .
-
This cancer 'prefers' young people
Time of Update: 2022-04-22
Although thyroid cancer has a horribly high incidence, it has been dubbed the " most mild " cancer , given the good postoperative outcomes and high survival rates .
Look in the mirror and tilt your head back slightly, exposing your neck .
-
Chin J Cancer Res: Phase III study by Prof. Baohui Han's team shows that QL1101 and bevacizumab are equally effective in the treatment of non-squamous non-small cell lung cancer
Time of Update: 2022-04-22
Recently, the Chinese Journal of Cancer Research published a 2-year follow-up update of a study by Professor Han Baohui's team from Shanghai Chest Hospital, which mainly evaluated the comparison of bevacizumab biosimilar QL1101 with bevacizumab in the treatment of non-patients.
-
Ther Adv Med Oncol: Peking Union Medical College Hospital team explores the best first-line treatment for HER2-altered advanced NSCLC patients in real world
Time of Update: 2022-04-22
immune blood vesselsA total of 293 patients were screened and 37 distinct HER2 mutations were identified, with the most common variant subtype being exon 20 insertions (ex20ins, n=246, 83.
-
Oncologist: Global multicenter real-world exploration of the efficacy of EGFR-TKIs in patients with rare EGFR-mutant NSCLC
Time of Update: 2022-04-22
To evaluate the efficacy of erlotinib, gefitinib, afatinib, or osimertinib as first- or second-line therapy in patients with NSCLC with rare EGFR mutations .
For patients who received EGFR TKIs as first-line therapy, the median TTF was 10.
-
Am Clin Nutrition: Meat consumption not associated with stomach cancer risk
Time of Update: 2022-04-22
Therefore, this study aimed to investigate the association between meat consumption and gastric cancer risk in Japanese men and women .
This study confirmed that meat consumption was not associated with the total number of gastric cancers in Japanese adults in a large prospective cohort study .
-
Transl Lung Cancer Res: Association of Baseline Tumor Size (BTS) with Outcomes in NSCLC Patients Receiving Immune Monotherapy or Combination Chemotherapy
Time of Update: 2022-04-22
Baseline tumor size (BTS) is a prognostic factor in non-small cell lung cancer (NSCLC) patients receiving immune checkpoint inhibitor monotherapy (ICI-mono) .
Baseline tumor size (BTS) is a prognostic factor in non-small cell lung cancer (NSCLC) patients receiving immune checkpoint inhibitor monotherapy (ICI-mono) .
-
European Radiology: Evaluation of left atrial remodeling in patients with breast cancer treated with adjuvant trastuzumab by CMRI
Time of Update: 2022-04-15
In this prospective cohort study of trastuzumab-treated breast cancer patients, there was a small but significant subclinical decrease in LAEF and a modest increase in LAmin after initiation of treatment , which returned to baseline 6 months after treatment was discontinued .